SG10202004535PA - Enhanced adoptive cell therapy - Google Patents

Enhanced adoptive cell therapy

Info

Publication number
SG10202004535PA
SG10202004535PA SG10202004535PA SG10202004535PA SG10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA SG 10202004535P A SG10202004535P A SG 10202004535PA
Authority
SG
Singapore
Prior art keywords
cell therapy
adoptive cell
enhanced
enhanced adoptive
therapy
Prior art date
Application number
SG10202004535PA
Inventor
Akseli Hemminki
Markus Vähä-Koskela
Siri Tähtinen
Vincenzo Cerullo
Original Assignee
Tilt Biotherapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilt Biotherapeutics Oy filed Critical Tilt Biotherapeutics Oy
Publication of SG10202004535PA publication Critical patent/SG10202004535PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202004535PA 2013-04-18 2014-04-16 Enhanced adoptive cell therapy SG10202004535PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20135387 2013-04-18

Publications (1)

Publication Number Publication Date
SG10202004535PA true SG10202004535PA (en) 2020-06-29

Family

ID=50513266

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202004535PA SG10202004535PA (en) 2013-04-18 2014-04-16 Enhanced adoptive cell therapy
SG11201508585PA SG11201508585PA (en) 2013-04-18 2014-04-16 Enhanced adoptive cell therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201508585PA SG11201508585PA (en) 2013-04-18 2014-04-16 Enhanced adoptive cell therapy

Country Status (14)

Country Link
US (2) US10647963B2 (en)
EP (2) EP3461491A1 (en)
JP (2) JP6580555B2 (en)
KR (3) KR20160002971A (en)
CN (2) CN111658670A (en)
AU (2) AU2014255733B2 (en)
BR (1) BR112015026417B1 (en)
CA (1) CA2909432A1 (en)
DK (1) DK2986311T3 (en)
ES (1) ES2708749T3 (en)
RU (1) RU2703438C2 (en)
SG (2) SG10202004535PA (en)
WO (1) WO2014170389A1 (en)
ZA (1) ZA201507790B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
DK3198009T3 (en) * 2014-09-24 2021-11-22 Salk Inst For Biological Studi ONCOLYTIC TUMOR VIRUSES AND METHODS OF USE
CN107406859A (en) * 2015-03-17 2017-11-28 倾斜生物医疗公司 The oncolytic adenovirus of encoding bispecific antibody and relative method and purposes
CN108138149A (en) * 2015-05-19 2018-06-08 不列颠哥伦比亚癌症局分支机构 Recombination oncolytic virus and application thereof
US20190038727A1 (en) * 2015-09-09 2019-02-07 Tvax Biomedical I, Llc Methods for combining adoptive t cell therapy with oncolytic virus adjunct therapy
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
JP7054527B2 (en) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ High-throughput assay to measure adenovirus replication kinetics
JP7015551B2 (en) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ Exogenous gene expression in therapeutic adenovirus to minimize its impact on viral dynamics
SG11201811600PA (en) 2016-06-30 2019-01-30 Oncorus Inc Pseudotyped oncolytic viral delivery of therapeutic polypeptides
FI20165814A (en) 2016-10-27 2018-04-28 Tilt Biotherapeutics Oy INTERLEUKIN 8 (IL-8) AS A PROGNOSTIC AND PROUDIC BIOMARKER AND COMPOSITIONS AND VECTORS FOR USE IN ONCOLYTIC IMMUNOTHERAPY
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018118967A1 (en) * 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CN108261426B (en) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 Pharmaceutical composition and its application in the drug for the treatment of tumour and/or cancer
KR20190128634A (en) * 2017-01-30 2019-11-18 에피센트알엑스, 인코포레이티드 Multiple transgene recombinant adenovirus
EA201990822A1 (en) * 2017-04-12 2020-01-09 Эписентарикс, Инк. IMMUNOMODULATING FUSION PROTEINS
AU2018251987A1 (en) * 2017-04-14 2019-12-05 Cg Oncology, Inc. Methods of treating bladder cancer
CN118147137A (en) * 2017-05-17 2024-06-07 西雅图儿童医院（Dba西雅图儿童研究所） Generation of mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy
CN109276580B (en) * 2017-07-21 2021-08-24 厦门大学 A virus for treating tumor
KR20200036874A (en) * 2017-08-03 2020-04-07 타이가 바이오테크놀로지스, 인코포레이티드 Methods and compositions for the treatment of cancer
KR20200055037A (en) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 Compositions and uses for chimeric antigen receptor T cell therapy
CN109554353B (en) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 Isolated recombinant oncolytic poxvirus, pharmaceutical compositions and use thereof in a medicament for the treatment of tumors and/or cancers
CN109576231B (en) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions and their use in medicaments for the treatment of tumors and/or cancers
CN107759701B (en) * 2017-10-27 2021-07-02 杭州优善生物科技有限公司 Chimeric antigen receptor, NK cell modified by chimeric antigen receptor, coding DNA, mRNA, expression vector, preparation method and application
CA3081436A1 (en) * 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
CN111542601A (en) * 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 Oncolytic virus (oncolytic immunotherapy) with expression control system providing optimal expression levels of loaded immune-derived genes ensuring safe and effective treatment even of metastatic cancer
US11975024B2 (en) 2017-12-19 2024-05-07 Musc Foundation For Research Development T regulatory (Treg) cell transplantation in osteogenesis imperfecta (OI)
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
CN108017716B (en) * 2018-01-02 2021-03-19 赖沛龙 Chimeric antigen receptor comprising C5aR intracellular domain, lentiviral vector, expression cell and drug
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
CN110101843A (en) * 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 A kind of anti-tumor protein and its application
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
KR20240067973A (en) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 Engineered immunostimulatory bacterial strains and uses thereof
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022536929A (en) 2019-06-14 2022-08-22 ティルト バイオセラピューティクス オサケユキチュア Combination therapy with oncolytic adenovirus and checkpoint inhibitor
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN114502736A (en) 2019-10-11 2022-05-13 蒂尔坦生物制药有限公司 Oncolytic viral vectors encoding interleukin-2 variant (vIL-2) polypeptides
WO2021097144A2 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
CN115768464A (en) 2020-03-10 2023-03-07 麻省理工学院 Methods of generating engineered memory-like NK cells and compositions thereof
BR112022017924A2 (en) 2020-03-10 2022-12-20 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR NPM1C-POSITIVE CANCER IMMUNOTHERAPY
US20230149485A1 (en) * 2020-04-07 2023-05-18 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered oncolytic adenovirus
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
JP2023539454A (en) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド Immunostimulatory bacterial-based vaccines, therapeutics and RNA delivery platforms
RU2753742C1 (en) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) RECOMBINANT STRAIN OF Ad6-hTERT-GMCSF CONTAINING EMBEDDING OF THE HUMAN TELOMERASE PROMOTER hTERT, AS WELL AS HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GENE, WHICH HAS SELECTIVE CYTOLYTIC ACTIVITY AGAINST TELOMERASE-POSITIVE TUMOR CELLS AND EXPRESSES ACTIVE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
CN112481284B (en) * 2020-12-07 2023-07-25 深圳瑞吉生物科技有限公司 mRNA (messenger ribonucleic acid) encoding CAR (CAR-T) gene, combined mRNA, construction method, CAR-T cell and application
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
EP4329786A1 (en) 2021-04-30 2024-03-06 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2022246646A1 (en) * 2021-05-25 2022-12-01 江苏万戎生物医药科技有限公司 Chimeric broad-spectrum oncolytic adenovirus with multiple mechanisms synergizing with and enhancing efficacy of immunotherapy, and application thereof in tumor treatment
CN113249342B (en) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 Chimeric broad-spectrum oncolytic adenovirus with multiple mechanism synergistic and synergistic immunotherapy and application thereof in tumor treatment
CN113398249A (en) * 2021-07-08 2021-09-17 中国人民解放军空军军医大学 Application of over-expressed chemokine CCL14 in preparation of medicine for treating tumors under participation of immune system
CN113832115A (en) * 2021-08-25 2021-12-24 居颂光 Fusion gene RIL-7 combined CCL19 recombinant oncolytic vaccinia virus and application thereof in preparation of antitumor drugs
CN118055776A (en) * 2021-10-04 2024-05-17 蒂尔坦生物制药有限公司 Oncolytic viral vectors encoding interleukin-7 (IL-7) polypeptides
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
CN118234851A (en) * 2021-11-19 2024-06-21 南开大学 Recombinant armed oncolytic viral compositions and their use in TIL adoptive therapy
WO2023194656A1 (en) 2022-04-08 2023-10-12 Tilt Biotherapeutics Oy Monoclonal pd-l1 antibodies
WO2023217072A1 (en) * 2022-05-09 2023-11-16 杭州微诺迈博生物科技有限公司 Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy
CN115969971B (en) * 2022-11-24 2023-08-18 珠海恩科生物科技有限公司 Application of composition in preparation of medicines for treating tumors
KR102603628B1 (en) * 2023-06-29 2023-11-16 국방과학연구소 Composition for differentiating, proliferating or activating natural killer cells, method for differentiating, proliferating or activating natural killer cells using the same, and natural killer cells cultured thereby

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
FR2709309B1 (en) 1993-08-25 1995-11-10 Centre Nat Rech Scient Cellular compositions, preparation and therapeutic uses.
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
EP1191105A1 (en) 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
ITMI20012110A1 (en) * 2001-10-12 2003-04-12 Keryos Spa MULTI-CISTRONIC VECTORS USABLE IN GENE TRANSFER PROTOCOLS
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
ES2276623B1 (en) * 2005-12-12 2008-06-01 Proyecto De Biomedicina Cima, S.L NEW ADENOVIRUS RECOMBINANTS OF CONDITIONED REPLICATION (CRAD).
EP1984007B1 (en) * 2006-02-13 2015-08-19 Oncolytics Biotech Inc. Use of low dose local immune suppression to enhance oncolytic viral therapy
MX340972B (en) 2008-10-08 2016-08-02 Intrexon Corp Engineered cells expressing multiple immunomodulators and uses thereof.
LT2379586T (en) * 2008-12-22 2017-03-10 Targovax Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI20090030A0 (en) * 2009-02-02 2009-02-02 Akseli Eetu Hemminki Oncolytic virus
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US9487800B2 (en) 2010-09-08 2016-11-08 Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
RU2013118724A (en) * 2010-09-24 2014-10-27 Онкос Терапьютикс Ой ONCOLITIC Adenovirus VECTORS AND RELATED METHODS AND APPLICATIONS
CN102154213B (en) * 2011-01-19 2012-07-25 郑骏年 Novel cytokine-induced killer (CIK) cells for carrying cytokine loaded double-regulated oncolytic adenovirus
CN103476943A (en) 2011-03-10 2013-12-25 普罗维克图斯药品公司 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus

Also Published As

Publication number Publication date
JP6580555B2 (en) 2019-09-25
KR20160002971A (en) 2016-01-08
WO2014170389A8 (en) 2015-11-05
ZA201507790B (en) 2016-12-21
AU2019216631B2 (en) 2021-04-29
RU2015148920A3 (en) 2018-06-22
EP2986311A1 (en) 2016-02-24
JP7114532B2 (en) 2022-08-08
US20150232880A1 (en) 2015-08-20
US20170137786A1 (en) 2017-05-18
ES2708749T3 (en) 2019-04-11
KR20210084651A (en) 2021-07-07
KR102502974B1 (en) 2023-02-23
CA2909432A1 (en) 2014-10-23
RU2703438C2 (en) 2019-10-16
AU2014255733B2 (en) 2019-05-16
CN105307671B (en) 2020-09-04
AU2014255733A1 (en) 2015-11-26
EP3461491A1 (en) 2019-04-03
US10787645B2 (en) 2020-09-29
SG11201508585PA (en) 2015-11-27
JP2016522805A (en) 2016-08-04
CN105307671A (en) 2016-02-03
CN111658670A (en) 2020-09-15
WO2014170389A1 (en) 2014-10-23
BR112015026417B1 (en) 2024-02-27
AU2019216631A1 (en) 2019-09-05
US10647963B2 (en) 2020-05-12
DK2986311T3 (en) 2019-02-25
JP2020011966A (en) 2020-01-23
RU2015148920A (en) 2017-05-24
KR20220056879A (en) 2022-05-06
BR112015026417A2 (en) 2017-09-05
EP2986311B1 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
ZA201507790B (en) Enhanced adoptive cell therapy
IL263026A (en) Ibrutinib combination therapy
HK1223553A1 (en) Cell
AU356417S (en) Battery
GB201303814D0 (en) Battery structure
EP2988346A4 (en) Cell case
GB201308440D0 (en) Therapeutic
GB201310755D0 (en) Therapy
GB201310031D0 (en) Cell
GB201312332D0 (en) Cell locations
EP2953200A4 (en) Battery
GB201207305D0 (en) Therapy
HK1202710A1 (en) Laminate cell
GB201318668D0 (en) Sonosensitive therapeutic
IL238174A0 (en) Combination therapy with volasertib
GB201307269D0 (en) Combination Therapy
GB201304038D0 (en) Treated cells and therapeutic uses
GB201518731D0 (en) Tumour Therapy
GB201304514D0 (en) Cell delivery
HK1221640A1 (en) Therapeutic peptide-expressing cells
GB201317589D0 (en) Cell
EP2996684A4 (en) Therapeutic methods
GB201320573D0 (en) T Cell
TWM476369U (en) Battery structure improvement
GB201309967D0 (en) Therapeutic combinations